Finance

Lists
N1BI34:BVMF
Neurocrine Biosciences Bdr
R$47.20
-1.56%
(-0.75) 1D
Nov 19, 5:29:53 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for N1BI34...
Open
R$50.00
High
R$50.00
Low
R$46.15
Mkt. cap
15.85B
Avg. vol.
1.75K
Volume
0.00
52-wk high
R$50.00
52-wk low
R$31.51
Shares outstanding
101.22M
No. of employees
2K
Open
R$50.00
High
R$50.00
Low
R$46.15
Mkt. cap
15.85B
Avg. vol.
1.75K
Volume
0.00
52-wk high
R$50.00
52-wk low
R$31.51
Shares outstanding
101.22M
No. of employees
2K
News stories
From web sources and news partners
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences Bdr
CEOKevin C. Gorman
Employees2.5K
Founded1992
HeadquartersSan Diego, California, United States
SectorHealth Care
IndustryBiotechnology
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
805.50M
814.50M
959.00M
1.12B
Cost of goods sold
275.80M
310.00M
346.70M
372.10M
Cost of revenue
275.80M
310.00M
346.70M
372.10M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
302.50M
318.50M
383.10M
356.60M
Operating expense
302.50M
318.50M
399.50M
391.60M
Total operating expenses
578.30M
628.50M
746.20M
763.70M
Operating income
227.20M
186.00M
212.80M
359.00M
Other non operating income
-
-
-
-
EBT including unusual items
239.40M
246.80M
162.20M
283.70M
EBT excluding unusual items
253.00M
214.10M
222.30M
363.70M
Income tax expense
85.70M
48.90M
17.80M
77.20M
Effective tax rate
35.80%
19.81%
10.97%
27.21%
Other operating expenses
-
-
-
-
Net income
153.70M
197.90M
144.40M
206.50M
Net profit margin
19.08%
24.30%
15.06%
18.39%
Earnings per share
1.88
1.94
2.85
3.29
Interest and investment income
25.80M
28.10M
12.40M
5.00M
Interest expense
-
-
-2.90M
-300.00K
Net interest expenses
25.80M
28.10M
9.50M
4.70M
Depreciation and amortization charges
-
-
-
-
EBITDA
234.70M
193.30M
237.60M
403.00M
Gain or loss from assets sale
-
-28.60M
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps